
US' loss, China's gain: Aid cuts may open doors for Beijing in Africa
Last week, the Chinese government pledged a Ksh1.8 billion ($14 million) grant to Kenya, one of the biggest development assistance packages from Beijing in the recent years.
The deal signed by Treasury Cabinet Secretary John Mbadi and Chinese ambassador to Kenya Guo Haiyan is meant to upgrade five key hospitals across the country.
But the announcement was pivotal, coming at a time the US, Kenya's main foreign aid donor, is cutting back on most of the money it used to give.
The Donald Trump administration has indicated it is truncating 5,341 contracts, initially provided mostly through USAid, worth some $75 billion. It greenlighted another 898 programmes worth $78 billion, although most of them will end within the next 11 months.
The decision which all but ends the existence of USAid, has policy experts warning of a bleak future. USAid spent $32.5 billion in Africa in the 2024 fiscal year, although, overall, the US sent some $41 billion to sub-Saharan Africa to fund humanitarian responses and programmes, such as health and climate initiatives.
Ethiopia was the top African recipient of USAid funding in 2023, with $1.37 billion, Somalia ($973 million) and DR Congo (943 million). Kenya received $436 million, with some of it going into refugee camps serving people from South Sudan and Somalia.
In Kenya, USAid had been the backbone of health services such as research and treatment of malaria, tuberculosis and HIV/Aids, and even bankrolled some nutritional programmes.
Now some of the programmes, such as HIV drugs, may be cut.
Some US politicians concede that a Chinese influence in future foreign aid will be inevitable.
Democrat Senators Jeanne Shaheen (New Hampshire), Ranking Member of the Senate Foreign Relations Committee, Chris Coons (Delaware), Cory Booker (New Jersey), Brian Schatz (Hawaii), Tammy Duckworth (Illinois) and Jacky Rosen (Nevada) argue that cutting down USAid would make it difficult for the US to counter China.
On March 14, 2025, the Democrats wrote to US Secretary of State Marco Rubio to provide answers to how the USAid cut will impact America's interests.'For less than 1 percent of our annual budget, the US builds partnerships around the globe that diminish the threat of terrorism, the spread of disease and build peace,' Senator Shaheen said.'I am still waiting to hear why this administration does not consider programmes that have eradicated polio, cut malaria deaths in half and saved 25 million lives through HIV treatment to be 'lifesaving.' China alone will benefit from this decline in American global leadership.'Their worry was that trump had terminated vital US foreign assistance projects, including in countries where the Washington maintains military bases, and cut critical vaccine and global health projects around the world.
The State Department ignored them.
But US funding cuts don't necessarily mean Beijing is jumping in. Some experts say China had already identified its niche.
Dr Adhere Cavince, a China-Africa scholar told The EastAfrican that US withdrawal obviously leaves a gap that is both inviting by also challenging.'Inviting because China can use the opportunity to strengthen its partnership with global South countries that heavily relied on US aid; challenging because China may not be keen to support the kind of programmes that the US did. They would instead double down on their competitive areas: Infrastructure development, trade, digital inclusion and capital development. They could also come in on the health front- supplies of medicines,' he said.
In Africa, China has constructed 'friendship' offices for the African Union, the Economic Community of West Africa, Intergovernmental Authority on Development and parliament buildings for Zimbabwe and Cameroon.
The US funding cuts may mean China will pump more money in social programmes, but only where their influence is strong, the scholar argues.
Read: US vs China: Who's fooling Africa?When Trump first suspended USAid, Kenya's Prime Cabinet Secretary Musalia Mudavadi said that African countries will have to wean themselves of aid, fast.'The geopolitics and shifting global dynamics being witnessed is a clear indicator that we should be looking at ways of being self-reliant moving into the future. We cannot afford to prevaricate. Other countries are making moves. We must make ours now,' Mr Mudavadi said on the side-lines of a UN Human Rights Council meeting in Geneva on February 28.
He said Africans must learn quick decision-making, and build stronger partnerships with private sector.
Some observers, however, say African countries will first face the shock, and may even be stuck in it for lack of capacity.
Dr Angela Muvumba Sellström, senior researcher at the Nordic Africa Institute in Uppsala, Sweden, says the abrupt termination of US support for HIV/Aids management and mitigation, for example, will pose a wide range of problems to individuals, communities and countries.'Here are the consequences: Individuals off antiretroviral medications will see their viral loads increase, and, depending on how long they've been living with HIV (and on treatment), will become vulnerable to opportunistic infections. They will then have to rely on the public sector for health care, increasing the disease burden on the system. They will be out of work and unable to support their families,' she told The EastAfrican'This has a ripple effect on livelihoods and the functioning of society.'It means productive parts of the population, who have been kept healthy through subsidised medication, will be felled by sickness and public health systems will struggle to cope with new infections, she warned. Given the way Africa struggled to manage pandemics, in the past, the continent will face a burden that will drug more people into poverty.
According to her, it is not that African governments should not take responsibility for their populations. The current geopolitical and socio-economic conditions, however, are not built for them to do so because they have no money.'And even when the Chinese step in, the basic need in African health systems, she argued, is a sustainable supply of medical services. African states should find ways to build their own drug production capacity – and that takes time. And while hospitals built by the Chinese would be a help, what about the medicines to treat people in these hospitals?'One solution, she said, is for African countries may still need multilateral lenders that have leverage with private sector and deal with the growing debt in Africa through an emergency plan to forgive some of the debt so these countries can reroute their resources to health crises caused by funding cuts.
Abdisaid M. Ali, chair of the Lome Security Forum, said Africa's next aid system should focus on strengthening government structures.'Foreign aid in Africa has been at an international bridge for the last six decades built on well-established western international aid structures and guarded by UN, international NGOs, and military institutions that have never ceded primacy to the host African governments. But the donors implemented their projects through parallel structures with the existing authorities which weakened most of these host governments,' he told The EastAfrican.'So, any non-traditional donors who could implement projects through the government entities would be considered as the most viable and effective partners.'
© Copyright 2022 Nation Media Group. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info).
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Arabian Post
25 minutes ago
- Arabian Post
MediLink Therapeutics Taps Major Banks for Hong Kong Float
MediLink Therapeutics Ltd. is preparing to launch an initial public offering in Hong Kong, having secured China International Capital Corp., JPMorgan Chase & Co. and Morgan Stanley as its lead advisers, according to people with knowledge of the matter. The move comes as the clinical-stage biotech firm seeks to capitalise on growing investor interest in advanced tumour-targeting therapies and consolidate its platform of antibody‑drug conjugates. Founded in 2020 and headquartered in Suzhou with R&D operations in Shanghai and Boston, MediLink has developed a proprietary ADC technology known as TMALIN®. The platform facilitates precise delivery of cytotoxic agents to tumour cells, with the intention of widening therapeutic windows for solid tumour treatments. Its pipeline includes programs that have advanced to clinical stages in both China and the United States, supported by a Series B financing round of approximately USD 70 million in 2022. MediLink's strategic engagement of three underwriters reflects heightened confidence in anchor investors and broader syndication. China International Capital Corp. brings deep roots in Chinese capital markets and extensive IPO experience in the biotech sector. JPMorgan and Morgan Stanley add global banking heft and access to international investors. ADVERTISEMENT CICC itself is emerging as a top-tier sponsor for Hong Kong listings. It led or co-led 19 IPOs for Chinese corporates last year, raising USD 3.84 billion, positioning it as a dominant force amid market revival. The engagement of internationally renowned banks alongside CICC is likely aimed at boosting MediLink's valuation and widening investor interest both locally and abroad. While IPO details remain confidential, analysts suggest MediLink could seek a valuation in the mid‑to‑high hundreds of millions of dollars. That would reflect both the advanced stage of its pipeline and prevailing market multiples for ADC developers. Comparable biotech flotations in Hong Kong and the U.S. have reflected growing appetite for oncology-focused platforms. Alongside listing ambitions, MediLink continues to advance its clinical and licensing goals. In March it unveiled preclinical data at the American Association for Cancer Research annual meeting; earlier in the year it received FDA clearance for its IND application for YL217, its lead candidate. YL201, another programme, received Breakthrough Therapy Designation in January for treatment of recurrent/metastatic nasopharyngeal carcinoma. The company has also pursued strategic licensing agreements with global pharmaceutical firms to expand development and commercialisation capabilities. A licensing deal under discussion ahead of the IPO is believed aimed at enhancing distribution reach while reinforcing MediLink's balance sheet. The IPO effort is part of a broader resurgence in biotech listings in Hong Kong, where authorities have eased regulations to attract innovation-driven offerings. CICC and other banks have ramped up support for ADC and gene therapy companies, signalling a turning point after a lull in listings. ADVERTISEMENT MediLink's choice of banks aligns with a wider trend: CICC has co-sponsored blockbuster floats including the forthcoming mega‑IPO of CATL, while banks like Goldman Sachs and Morgan Stanley have also participated. In this context, MediLink is positioning itself to tap both deep domestic networks and international capital. Stakeholder sentiment appears optimistic. MediLink's management team, comprised of co‑founders Tony Xue and Jiaqiang Cai alongside C‑suite leaders experienced in drug development and financial strategy, has overseen steady progress in its ADC pipeline and established global partnerships. Jason Li's appointment as CFO in 2023 reportedly strengthened the company's capital market readiness. Market observers highlight challenges ahead. ADC development remains capital-intensive, clinical risks high, and competition fierce among domestic and international peers. Success will hinge on late‑stage data and licensing traction. At the same time, geopolitical tensions and volatility in Hong Kong equity markets may affect investor sentiment. MediLink must also navigate post‑IPO obligations, including regulatory reporting and corporate governance under Hong Kong's Main Board requirements. Mitigating execution risk will be critical, underscoring the role of its chosen bankers in underwriting diligence and market support. Analysts describe the listing as a pivotal moment: it offers the backing to fund Phase II/III efforts while elevating MediLink's corporate profile. For banks, it reinforces Hong Kong's appeal as a biotech capital market when compared with established centres like Nasdaq. With its IPO process underway, MediLink now awaits market timing and regulatory clearances before formally filing a prospectus. The company is expected to continue advancing clinical data, strengthening licensing ties, and preparing investor materials aligned with regulatory requirements.


Arabian Post
10 hours ago
- Arabian Post
Ethiopia Targets 8.9 % Growth as Budget Widens
Ethiopia's finance minister has announced that the economy is projected to expand by 8.9 % in the fiscal year beginning 8 July 2025, alongside a modest increase in the budget deficit amid structural reforms. Finance Minister Ahmed Shide addressed parliament on Tuesday, outlining the forecast for the next fiscal year, citing an acceleration in real GDP growth from an estimated 8.4 % this year to 8.9 % next year. The state budget deficit is expected to rise slightly to 2.2 % of GDP, compared to 2.1 % in the current year. Total government expenditure is projected at 1.9 trillion birr, equivalent to around US $14 billion. This positive outlook is deeply anchored in ongoing reforms backed by an International Monetary Fund programme. These include the liberalisation of the exchange rate, debt restructuring negotiations, and the establishment of the Ethiopian Securities Exchange, which opened in January after a 50‑year absence. ADVERTISEMENT The cabinet's approval of the new budget earlier this month signalled a strategic reallocation of resources, with spending set to increase by 31 % compared to the previous year's 971 billion birr. A significant portion is earmarked for national security, productivity enhancement, and disaster relief, including continued subsidies for fuel, fertiliser, oil and medicines—a move aimed at dampening inflationary pressure on households. Reforms and their impacts The IMF programme that began in July 2024 has been a linchpin in the reform agenda. In April, State Finance Minister Eyob Tekalign reported that the third review of the four‑year US $3.4 billion loan arrangement had reached staff‑level agreement, with approval by the IMF executive board anticipated this month. Subsequent draws will hinge on continued reform progress, notably debt restructuring. Debt, inflation and exchange rate liberalisation remain pressing concerns. A draft budget revealed that 463 billion birr—nearly 39 % of recurrent expenditure—will go towards debt servicing, surpassing planned capital outlays. The government intends to restructure approximately US $3.5 billion in external liabilities through agreements in upcoming weeks. Bondholder writedowns are expected as part of a broader debt resolution strategy. Monetary reforms have lessened inflation, which reached 29.2 % in 2022/23, and narrowed the spread between official and parallel exchange rates. Foreign reserves have rebounded, tripling to US $3.6 billion, easing foreign exchange shortages. These financial indicators have been central in IMF assessments. Policy makers are awaiting formal debt restructuring talks this summer with official and private creditors alike, guided by the G20 Common Framework. Iran‑timed agreements with Chinese policy banks, the U.S. International Development Finance Corporation and other funders are being explored to support infrastructure and development needs. Regional comparisons and strategic outlook Ethiopia remains one of sub‑Saharan Africa's highest growth economies, although still below the pre‑covid annual average of around 10 %. The country's trajectory continues to be shaped by recovery from the Tigray war, covid‑19 disruptions, droughts and locust invasions, but ongoing reforms are expected to unlock further expansion. The imminent fiscal year budget, combining a steep rise in expenditure with a stabilising deficit, underscores a cautious but ambitious strategy: focusing on debt management, reform momentum and public service delivery, rather than unfettered spending. Key stakeholders, including opposition figures such as Desalegn Chane of the National Movement of Amhara, have voiced concern over rising tax burdens amid steady living costs and a depreciating birr. Criticism has targeted new levies on motor vehicles and excise taxes, with claims these conflict with subsidy policies. The finance minister, however, defended these as necessary for fiscal resilience and revenue expansion. Broader reform dynamics have been influenced by Prime Minister Abiy Ahmed's economic agenda, including the launch of Ethiopia's first stock market since the Haile Selassie era, currency liberalisation, and opening the banking sector to foreign investment. These steps have been deemed essential to securing up to US $27 billion in external funding from IMF, World Bank, UAE, China and others over the next four years. Looking ahead The projection of roughly 8.9 % GDP growth signals confidence that reforms are gaining traction, even as the government prepares to finance a wider budget and service rising debt. The success of the IMF programme's next review, debt restructuring outcomes, and reform implementation will determine whether Ethiopia can sustain its economic momentum and weather domestic and global headwinds.


Middle East Eye
10 hours ago
- Middle East Eye
US Secretary of State Rubio terminates all USAID positions abroad: Report
By the end of September, there will be no such thing as the United States Agency for International Development (USAID), The Guardian reported on Monday, because all of its overseas staff will be terminated. Many, if not most, are local hires who have depended on a USAID salary for years and sometimes decades to support their families. The Guardian attributed the revelation to a State Department cable that it had obtained. It said the chiefs of mission at embassies in more than 100 countries have been notified that a significant overhaul is coming. 'The Department of State is streamlining procedures under National Security Decision Directive 38 to abolish all USAID overseas positions,' the cable said. The State Department and Secretary of State Marco Rubio 'will assume responsibility for foreign assistance programming previously undertaken by USAID' from 15 June, it added. New MEE newsletter: Jerusalem Dispatch Sign up to get the latest insights and analysis on Israel-Palestine, alongside Turkey Unpacked and other MEE newsletters In early March, Rubio said that US President Donald Trump's purge of the six-decade-old USAID was complete and that 5,200 of its 6,200 programmes had been eliminated. The remaining programmes, he said, would now be administered 'more effectively' under the State Department and in consultation with Congress. The axing of the aid agency was an initiative from the Elon Musk-led Department of Government Efficiency, which aimed to save Washington billions in what it believed was unnecessary spending. Among its earliest finds was what the administration described as $50worth of condoms sent by the US "to Hamas". It was then revealed that it was a programme to prevent sexually transmitted diseases in the rural province of Gaza, Mozambique. Musk departed the administration two weeks ago. Since the Trump administration announced an immediate suspension of all foreign assistance, blocking ongoing aid programmes and freezing new funding, humanitarian workers around the world have been trying to work out exactly what this means for the millions of vulnerable people they are trying to keep alive. Middle East Eye reported on the impact of the initial USAID cuts on 1.8 million Sudanese experiencing famine. Food boxes sent by the US were rotting in warehouses because the agency no longer provided the money needed for the actual distribution. Since 1946, the Middle East and North Africa have been the biggest recipients of US financial assistance. Between April 2023 and April 2024, Congress appropriated around $9bn for the region. While most of the aid went towards military assistance, a fraction was funnelled into democracy programmes via USAID and the National Endowment for Democracy, a quasi-autonomous agency funded largely by the US Congress. MEE reported in May of this year that the Trump cuts to USAID have already impacted human rights defenders in the region who were reliant on the small grants to relocate and resettle abroad. Although modest in scope, the money provided a lifeline for exiled human rights activists.